X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5375) 5375
Publication (422) 422
Book Review (60) 60
Magazine Article (29) 29
Book / eBook (25) 25
Conference Proceeding (19) 19
Book Chapter (18) 18
Web Resource (14) 14
Reference (8) 8
Dissertation (6) 6
Data Set (2) 2
Journal / eJournal (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3028) 3028
male (2613) 2613
animals (2431) 2431
nootropic agents - therapeutic use (2352) 2352
nootropic agents - pharmacology (1959) 1959
index medicus (1944) 1944
female (1482) 1482
neurosciences (1388) 1388
rats (1259) 1259
alzheimer disease - drug therapy (1222) 1222
pharmacology & pharmacy (1192) 1192
aged (1091) 1091
alzheimer's disease (857) 857
alzheimers-disease (787) 787
memory (732) 732
mice (726) 726
nootropic agents - administration & dosage (719) 719
psychiatry (698) 698
cognition - drug effects (681) 681
dementia (660) 660
middle aged (658) 658
clinical neurology (655) 655
treatment outcome (628) 628
dose-response relationship, drug (559) 559
nootropic agents - adverse effects (553) 553
piperidines - therapeutic use (535) 535
indans - therapeutic use (528) 528
disease models, animal (515) 515
memory - drug effects (511) 511
brain (505) 505
donepezil (501) 501
rats, wistar (485) 485
brain - drug effects (468) 468
adult (467) 467
cholinesterase inhibitors - therapeutic use (465) 465
aged, 80 and over (452) 452
cognition disorders - drug therapy (448) 448
cognition (447) 447
double-blind (428) 428
neuropsychological tests (416) 416
maze learning - drug effects (415) 415
double-blind method (401) 401
rats, sprague-dawley (374) 374
hippocampus - drug effects (370) 370
time factors (339) 339
alzheimer disease - psychology (313) 313
nootropics (308) 308
neurons - drug effects (306) 306
brain - metabolism (301) 301
analysis (300) 300
hippocampus (289) 289
geriatrics & gerontology (288) 288
neurology (287) 287
avoidance learning - drug effects (276) 276
dementia - drug therapy (267) 267
behavior, animal - drug effects (266) 266
memory disorders - drug therapy (266) 266
nootropic agents - chemistry (235) 235
neuroprotective agents - pharmacology (233) 233
alzheimer disease - diagnosis (230) 230
article (226) 226
chemistry, medicinal (224) 224
drug therapy (222) 222
oxidative stress (221) 221
placebo-controlled trial (218) 218
hippocampus - metabolism (217) 217
long-term potentiation (215) 215
efficacy (214) 214
neurons - metabolism (212) 212
rivastigmine (210) 210
neuroprotective agents - therapeutic use (209) 209
nootropic agents (206) 206
nootropic agents - pharmacokinetics (201) 201
galantamine - therapeutic use (200) 200
mice, inbred c57bl (198) 198
rat (197) 197
behavioral sciences (194) 194
piracetam (192) 192
neurons (191) 191
motor activity - drug effects (189) 189
alzheimer disease - metabolism (187) 187
piracetam - pharmacology (187) 187
alzheimers disease (185) 185
clinical trials as topic (185) 185
drug therapy, combination (185) 185
randomized controlled trials as topic (185) 185
aging (184) 184
random allocation (184) 184
cognitive ability (182) 182
cholinesterase inhibitors - pharmacology (181) 181
research (180) 180
cognition disorders - etiology (179) 179
galantamine (178) 178
alzheimer disease - physiopathology (176) 176
medicine, general & internal (176) 176
nootropic (175) 175
piperidines - pharmacology (173) 173
acetylcholine (170) 170
severity of illness index (170) 170
drugs (168) 168
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (13) 13
Gerstein Science - Stacks (12) 12
UofT Schools - Stacks (2) 2
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4747) 4747
Russian (351) 351
German (145) 145
French (47) 47
Japanese (45) 45
Spanish (45) 45
Chinese (19) 19
Hungarian (19) 19
Italian (13) 13
Czech (9) 9
Polish (8) 8
Ukrainian (8) 8
Dutch (5) 5
Portuguese (4) 4
Danish (3) 3
Finnish (3) 3
Turkish (2) 2
Romanian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2017, Schriften des Instituts für Angewandte Ethik e.V., ISBN 3826060989, Volume Band 16, 129
Book
2015, 2015, Handbook of experimental pharmacology, ISBN 3319165216, Volume 228, viii, 470
This book highlights the behavioral and neurobiological issues relevant for drug development, reviews evidence for an innovative approach for drug discovery... 
Development | Cognitive therapy | Cognitive neuroscience | Nootropic agents | Medicine | Neurology | Neurosciences | Toxicology | Psychopharmacology | Biomedicine | Pharmacology/Toxicology
Book
Nature Reviews Drug Discovery, ISSN 1474-1776, 2014, Volume 13, Issue 6, pp. 433 - 444
The liver X receptors (LXRs) are pivotal regulators of lipid homeostasis in mammals. These transcription factors control the expression of a battery of genes... 
BINDING CASSETTE TRANSPORTER | BILIARY STEROL SECRETION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | REVERSE CHOLESTEROL TRANSPORT | ALZHEIMERS-DISEASE | LOW-DENSITY-LIPOPROTEIN | PROLIFERATOR-ACTIVATED RECEPTOR | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | EXPRESSION IN-VITRO | ATHEROSCLEROSIS SUSCEPTIBILITY | LXR-ALPHA | Intestines - drug effects | Drugs, Investigational - pharmacology | Humans | Drugs, Investigational - therapeutic use | Intestines - metabolism | Orphan Nuclear Receptors - metabolism | Brain - metabolism | Drugs, Investigational - chemistry | Protein Isoforms - metabolism | Liver - drug effects | Alzheimer Disease - prevention & control | Liver X Receptors | Drug Design | Neurons - metabolism | Hypolipidemic Agents - chemistry | Drug Evaluation, Preclinical | Neurons - drug effects | Hypolipidemic Agents - adverse effects | Nerve Tissue Proteins - antagonists & inhibitors | Molecular Targeted Therapy - adverse effects | Atherosclerosis - drug therapy | Liver - metabolism | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Clinical Trials as Topic | Hypolipidemic Agents - pharmacology | Nootropic Agents - adverse effects | Nootropic Agents - chemistry | Drug Discovery | Atherosclerosis - metabolism | Brain - drug effects | Nerve Tissue Proteins - metabolism | Orphan Nuclear Receptors - antagonists & inhibitors | Animals | Signal Transduction - drug effects | Alzheimer Disease - metabolism | Lipid Metabolism - drug effects | Hypolipidemic Agents - therapeutic use | Atherosclerosis - prevention & control | Nootropic Agents - pharmacology | Protein Isoforms - antagonists & inhibitors | Care and treatment | Research | Drug discovery | Patient outcomes | Risk factors | Atherosclerosis
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 01/2016, Volume 59, Issue 1, pp. 114 - 131
Journal Article
Progress on the study of the effects of aging and nootropic drugs on membrane fluidity of neurons, 12/2005
Membrane fluidity means the fluidity of membrane lipid in the unit membrane. The changes of neuronal membrane potential, ion flux, release and binding of... 
Membrane fluidity | Neuron | Nootropic drugs | Aging
Journal
AAPS Journal, ISSN 1550-7416, 04/2013, Volume 15, Issue 2, pp. 324 - 336
The therapeutic effects of curcumin in treating Alzheimer's disease (AD) depend on the ability to penetrate the blood-brain barrier. The latest nanoparticle... 
nanocurcumin | pharmacokinetic | Alzheimer's disease | oral route | behavior tests | PERMEABILITY | MEMORY DEFICITS | AMYLOID-BETA PROTEIN | FORMULATION | MICROPARTICLES | CELLULAR UPTAKE | BIOAVAILABILITY | MOUSE MODEL | A-BETA | CHEMOPREVENTIVE AGENT | PHARMACOLOGY & PHARMACY | Memory - drug effects | Curcumin - chemistry | Male | Polyethylene Glycols - chemistry | Curcumin - administration & dosage | Alzheimer Disease - pathology | Brain - metabolism | Nanoparticles | Plaque, Amyloid | Madin Darby Canine Kidney Cells | Behavior, Animal - drug effects | Female | Alzheimer Disease - psychology | Lactates - chemistry | Disease Models, Animal | Administration, Oral | Conditioning (Psychology) - drug effects | Drug Stability | Nootropic Agents - pharmacokinetics | Curcumin - pharmacokinetics | Alzheimer Disease - drug therapy | Mice, Transgenic | Technology, Pharmaceutical - methods | Nootropic Agents - blood | Permeability | Maze Learning - drug effects | Nootropic Agents - chemistry | Chemistry, Pharmaceutical | Blood-Brain Barrier - metabolism | Brain - drug effects | Particle Size | Fear | Povidone - chemistry | Animals | beta-Cyclodextrins - chemistry | Nootropic Agents - administration & dosage | Dogs | Brain - pathology | Mice | Alzheimer Disease - genetics | Nanotechnology | Alzheimer Disease - blood | Brain | Powders | Analysis | Drugstores | Medical tests | Cyclodextrins | Biopolymers | Polyols | Block copolymers
Journal Article
British Journal of Nutrition, ISSN 0007-1145, 07/2014, Volume 112, Issue 2, pp. 203 - 213
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 07/2015, Volume 764, pp. 497 - 507
Novel 2,3-benzodiazepine and related isoquinoline derivatives, substituted at position 1 with a 2-benzothiophenyl moiety, were synthesized to produce compounds... 
Benzothiophene | Nootropic agents | GABA | GABA A antagonist | Isoquinoline | Extrasynaptic receptors | 2,3-Benzodiazepine | Object recognition test | SUBTYPES | GARA | SUBUNIT COMPOSITION | A RECEPTORS | PYRAMIDAL NEURONS | GABA(A) antagonist | PHARMACOLOGY | ANIMAL-MODELS | ION-CHANNEL | PHARMACOLOGY & PHARMACY | RAT-BRAIN | ANTAGONISTS | TONIC INHIBITION | Capillary Permeability | Seizures - prevention & control | Benzodiazepines - chemical synthesis | Nootropic Agents - metabolism | Humans | Motor Activity - drug effects | Male | Structure-Activity Relationship | GABA-A Receptor Antagonists - metabolism | Anticonvulsants - pharmacology | Seizures - chemically induced | Dose-Response Relationship, Drug | HEK293 Cells | Receptors, GABA-A - drug effects | Behavior, Animal - drug effects | Molecular Structure | Benzodiazepines - metabolism | Disease Models, Animal | GABA-A Receptor Antagonists - pharmacology | Benzodiazepines - pharmacology | Anticonvulsants - chemical synthesis | Xenopus laevis | Anticonvulsants - metabolism | Nootropic Agents - chemical synthesis | Rats, Sprague-Dawley | Anticonvulsants - toxicity | Blood-Brain Barrier - metabolism | GABA-A Receptor Antagonists - chemical synthesis | Nootropic Agents - toxicity | Animals | Recognition (Psychology) - drug effects | Benzodiazepines - toxicity | Receptors, GABA-A - genetics | Mice | Pentylenetetrazole | Receptors, GABA-A - metabolism | GABA-A Receptor Antagonists - toxicity | Nootropic Agents - pharmacology
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 09/2017, Volume 139, pp. 40 - 55
Many chronic human diseases, including multiple neurodegenerative diseases, are associated with deleterious protein aggregates, also called protein amyloids.... 
Covalent mechanisms | Non-covalent mechanisms | Amyloid inhibitor | Natural products | Inhibition mechanisms | CLINICAL-TRIAL | PROTEIN AGGREGATION | ALZHEIMERS-DISEASE | SOLID DISPERSION | TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE | ALPHA-SYNUCLEIN AGGREGATION | BETA-PEPTIDE AGGREGATION | A-BETA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | AROMATIC-INHIBITOR | Amyloidosis - prevention & control | Drugs, Investigational - pharmacology | Antioxidants - chemistry | Nootropic Agents - metabolism | Antioxidants - metabolism | Healthy Diet | Humans | Polyphenols - pharmacology | Drugs, Investigational - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Biological Products - pharmacology | Flavonoids - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Polyphenols - metabolism | Amyloidogenic Proteins - antagonists & inhibitors | Drugs, Investigational - chemistry | Protein Aggregation, Pathological - prevention & control | Amyloidosis - diet therapy | Drug Design | Flavonoids - pharmacology | Protein Aggregation, Pathological - diet therapy | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Chelating Agents - therapeutic use | Biological Products - therapeutic use | Chelating Agents - chemistry | Nootropic Agents - therapeutic use | Amyloidosis - drug therapy | Antioxidants - pharmacology | Chelating Agents - pharmacology | Nootropic Agents - chemistry | Drug Discovery | Protein Aggregation, Pathological - drug therapy | Amyloidogenic Proteins - metabolism | Antioxidants - therapeutic use | Biological Products - chemistry | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Flavonoids - metabolism | Polyphenols - chemistry | Biological Products - metabolism | Polyphenols - therapeutic use | Chelating Agents - metabolism | Dietary Supplements | Flavonoids - chemistry | Amyloidosis - metabolism | Nootropic Agents - pharmacology | Medicine, Experimental | Medical research | Nervous system diseases | Glycoproteins | Drug discovery | Index Medicus
Journal Article
Neuropharmacology, ISSN 0028-3908, 01/2013, Volume 64, pp. 114 - 123
Previous studies have demonstrated that cognitive function can be restored in mouse models of Alzheimer's disease (AD) following administration of sildenafil,... 
PDE5 | Tadalafil | Alzheimer's disease | Memory | Blood–brain barrier | Blood-brain barrier | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | ALZHEIMERS-DISEASE | MEMORY DEFICITS | GLYCOGEN-SYNTHASE KINASE-3 | CGMP-BINDING | NEUROSCIENCES | INHIBITION | MESSENGER-RNA | NITRIC-OXIDE | GMP PATHWAY | OBJECT RECOGNITION | PHARMACOLOGY & PHARMACY | Gene Expression Regulation, Enzymologic - drug effects | Sulfones - therapeutic use | Species Specificity | Nootropic Agents - metabolism | Humans | Half-Life | Macaca fascicularis | Male | Carbolines - metabolism | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Brain - metabolism | Sildenafil Citrate | Tissue Distribution | Cognition Disorders - prevention & control | Cognition Disorders - etiology | Phosphodiesterase 5 Inhibitors - metabolism | Female | Phosphodiesterase 5 Inhibitors - therapeutic use | Purines - therapeutic use | Carbolines - blood | Carbolines - therapeutic use | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Disease Models, Animal | Phosphodiesterase 5 Inhibitors - blood | Mice, Inbred C57BL | Nootropic Agents - pharmacokinetics | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Mice, Transgenic | Piperazines - therapeutic use | Nootropic Agents - blood | Blood-Brain Barrier - metabolism | Brain - drug effects | Animals | Alzheimer Disease - metabolism | Brain - pathology | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Mice | Carbolines - pharmacokinetics | Alzheimer Disease - genetics | Neurosciences | Messenger RNA | Analysis | Smart drugs and nutrients | Universities and colleges
Journal Article
American Journal of Clinical Nutrition, ISSN 0002-9165, 03/2015, Volume 101, Issue 3, pp. 538 - 548
Background: Recent evidence has indicated that flavanol consumption may have many health benefits in humans, including improved cognitive activities.... 
Lipid peroxidation | Insulin resistance | Cocoa flavanols | Blood pressure | Cognitive function | cognitive function | blood pressure | PROANTHOCYANIDINS | cocoa flavanols | PERFORMANCE | CHOCOLATE | FLAVAN-3-OLS | RICH COCOA | lipid peroxidation | IMPAIRMENT | CARDIOVASCULAR HEALTH | NUTRITION & DIETETICS | MOOD | INSULIN-RESISTANCE | insulin resistance | BRAIN | Beverages - adverse effects | Flavonols - adverse effects | Follow-Up Studies | Humans | Antihypertensive Agents - administration & dosage | Flavonols - therapeutic use | Hypertension - drug therapy | Male | Cognition | Cognitive Dysfunction - prevention & control | Cacao - adverse effects | Aged, 80 and over | Aging | Female | Flavonols - administration & dosage | Hypertension - diet therapy | Double-Blind Method | Dairy Products - adverse effects | Cognitive Dysfunction - metabolism | Insulin Resistance | Nootropic Agents - therapeutic use | Combined Modality Therapy | Antihypertensive Agents - therapeutic use | Cacao - chemistry | Nootropic Agents - adverse effects | Antihypertensive Agents - adverse effects | Hypertension - metabolism | Antioxidants - therapeutic use | Nootropic Agents - administration & dosage | Antioxidants - administration & dosage | Antioxidants - adverse effects | Aged | Lipid Peroxidation | Cohort Studies | Medical research | Flavonoids | Flavones | Bioflavonoids | Nutritional aspects | Medicine, Experimental | Research | Cocoa | Health aspects
Journal Article